Olympus Partners has acquired PAI Pharma, a US-based manufacturer of generic oral liquids. No financial terms were disclosed. Kurt Orlofski serves as CEO of PAI. PAI Pharma has two large manufacturing ...

Permanent Secretary Dr. Jemesa Tudravu says the scheme is for patients who may struggle to obtain medication from hospitals ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: [email protected] ...

Dr. Blackman co-founded Day One Biopharmaceuticals in 2018 with a vision to identify, acquire, and develop promising new treatments to address childhood cancers. Under Dr. Blackman’s leadership, Day ...

Syngene is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

At the proposed price, Ascentage Pharma Group International would command a fully diluted market value of $1.8 billion, noted the company, whose shares rose 13.7% to HK$44.00 following the ...